On Monday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Catamaran Corporation (NASDAQ:CTRX), Horizon Pharma plc (NASDAQ:HZNP), Molycorp, Inc. (NYSE:MCP), Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)
Catamaran Corporation (NASDAQ:CTRX), with shares gained 23.82%, closed at $59.83, hitting new 52-week high of $60.24.
Horizon Pharma plc (NASDAQ:HZNP), with shares jumped 18.20%, settled at $25.78.
Molycorp, Inc. (NYSE:MCP),with shares climbed 14.69%, and closed at $0.367.
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE), surged 14.30%, and closed at $15.35.
Latest NEWS regarding these Stocks are depicted underneath:
Catamaran Corporation (NASDAQ:CTRX)`
Catamaran Corporation (CTRX), and OptumRx, declared that they have agreed to combine. OptumRx is UnitedHealth Group’s [NYSE:UNH] free-standing pharmacy care services business.
The contract calls for the attainment of Catamaran’s outstanding ordinary stock for $61.50 per share in cash. The transaction is predictable to close during the fourth quarter of 2015, subject to Catamaran shareholders’ approval, regulatory approvals and other customary closing conditions. The combination diversifies OptumRx’s customer and business mix, while accelerating its technology leadership and flexible service offerings.
The attainment is predictable to be accretive to UnitedHealth Group’s net earnings in the area of $0.30 per share in 2016. UnitedHealth Group plans to finance the attainment from existing cash resources and new debt. The corporation affirmed its $6.00 to $6.25 per share earnings outlook assuming the absorption of all merger costs, the ongoing commitment to advance its dividend policy as planned, and a continued but moderated level of share repurchase.
Upon closing, Mark Thierer , Catamaran’s chairman and chief executive officer, will serve as chief executive officer of OptumRx and Timothy Wicks , the current chief executive officer of OptumRx, will become president. Jeff Park , who presently serves Catamaran as executive vice president, Operations, will become the chief operating officer for OptumRx. Jeffrey Grosklags , presently the chief financial officer of OptumRx, will continue in that role.
Larry Renfro , chief executive officer of Optum said, “Catamaran’s capabilities are impressive and their leadership team has delivered the fastest growth in the industry. We believe the combination of the two companies will create a unique offering in the industry unparalleled by current participants. Optum’s longstanding business relationship with Catamaran as a technology partner means we operate on the same adjudication platform, simplifying integration and giving us confidence our combined organizations will quickly become an innovative force moving the pharmacy care services marketplace forward. We believe this combination will create noteworthy value for health plan, government, third party administrator and employer customers and, most importantly, the individual consumers who depend on us for accurate, affordable and convenient pharmacy benefit products and services.”
Catamaran Corporation provides pharmacy benefit administration (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefits administration industry in North America.
Horizon Pharma plc (NASDAQ:HZNP)
Horizon Pharma plc (HZNP), declared they have reached a definitive contract under which Horizon Pharma will attain all of the issued and outstanding shares of Hyperion’s ordinary stock for $46.00 per share in cash or about $1.1 billion on a fully diluted basis. The per share consideration represents a premium of about 35 percent to Hyperion’s volume weighted average price for the trailing 60-days. The projected transaction has been unanimously approved by both companies’ boards of directors.
Horizon has secured $900 million in debt commitments from Citigroup Global Capital Markets Inc. and Jefferies LLC, which in addition to Horizon’s cash and cash equivalents, is accessible to finance the transaction, repay Horizon’s $300 million Senior Secured Credit Facility and pay fees in addition to expenses related to the transaction. Horizon plans to replace a portion of the debt commitments through new debt issuances and the use of Hyperion’s cash and cash equivalents.
Jefferies LLC, Citigroup Global Markets Inc. and Cowen and Corporation acted as advisors to Horizon Pharma in the transaction. Citigroup Global Markets Inc. and Jefferies LLC are initial lenders and lead arrangers for the debt commitments in place to finance the transaction. Horizon Pharma’s legal advisors are Cooley LLP and McCann FitzGerald.
Centerview Partners LLC acted as financial advisor and offered a fairness opinion to Hyperion and Shearman & Sterling LLP acted as legal advisor. Houlihan Lokey Capital, Inc. also offered financial advice to the board of Hyperion.
Horizon Pharma plc, a specialty biopharmaceutical corporation, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally.
Molycorp, Inc. (NYSE:MCP)
Formerly on March 16, Molycorp, Inc. (MCP), declared financial and operating results for the fourth quarter and full year 2014.
FOURTH QUARTER 2014 RESULTS:
The Corporation stated merged net proceeds of $116.2 million, a 6% decrease over the third quarter of 2014. The decrease in proceeds was largely driven by a shifting product mix, lower sales volumes from all segments, except for Rare Metals’, and softened pricing for rare earths.
On the other hand, The Corporation stated merged net proceeds of $475.6 million, a 14% decrease as contrast to the full year 2013. The decrease in proceeds was largely driven by softened rare earth pricing.
Molycorp, Inc. produces and sells rare earths and rare metal materials in the United States and internationally. The corporation’s Resources segment extracts rare earth minerals, counting light rare earth concentrates; rare earth oxides (REO), such as lanthanum, cerium, and neodymium-praseodymium; heavy rare earth concentrates, which comprise samarium, europium, gadolinium, terbium, dysprosium, and others; and SorbX and PhosFIX, a line of rare earth-based water treatment products.
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)
Concert Pharmaceuticals, Inc. (CNCE), declared the completion of its formerly declared underwritten public offering of 3,300,000 shares of its ordinary stock. All shares in the offering were sold by Concert at a public offering price of $15.15 per share. Net proceeds to Concert are predictable to be about $46.7 million, after deducting underwriting discounts and commissions and estimated offering expenses and not counting any proceeds to be received by Concert if the underwriters exercise their 30-day option to purchase up to an additional 495,000 shares of our ordinary stock.
Wells Fargo Securities and JMP Securities are acting as joint book-running managers for the offering. Baird and Roth Capital Partners are acting as co-managers.
Concert Pharmaceuticals, Inc., a clinical stage biopharmaceutical corporation, discovers and develops small molecule drugs for central nervous system disorders, genetic diseases, renal disease, inflammatory disease, and cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
